Karam and colleagues report a phase I/Ib trial in patients with HNSCC treated with neoadjuvant SBRT and anti-PD-L1, and perform high-dimensional analyses of immune correlates of response in the tissue microenvironment and peripheral blood.
- Laurel B. Darragh
- Michael M. Knitz
- Sana D. Karam